Kevin Whaley

Kevin Whaley has worked for the last 30 years on the development of MPTs to prevent sexually transmitted diseases and unintended pregnancy. He co-founded Mapp Biopharmaceutical to develop antibody-based MPTs, therapeutics and mucosal vaccines that are appropriate for large, cost-sensitive, global health markets.

Share

Spread the word about the promise of MPTs.

Collaborate

We will go further together – join the movement for MPTs.

Contribute

Your financial and in-kind support can help make MPTs a reality.